Form 4: MANGOCEUTICALS Director Kenny Myers Receives 100,000 Share Bonus

MANGOCEUTICALS, INC. Director Kenny Myers was granted 100,000 shares of common stock as a discretionary bonus for his services.

Summary

• Director Kenny Myers of MANGOCEUTICALS, INC. (MGRX) acquired 100,000 shares of common stock.
• The shares were issued as a discretionary bonus in consideration for services rendered as a member of the Board of Directors.
• The grant was made under the registrant's Second Amended and Restated 2022 Equity Incentive Plan.
• Following this transaction, Mr. Myers directly beneficially owns a total of 136,667 shares of common stock.
• The transaction date was September 9, 2025, and the shares were acquired at a price of $0, indicating a grant rather than a purchase.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even as a bonus, generally indicates confidence in the company's future and aligns insider interests with shareholders. This is a positive signal, though not a direct investment of personal capital.

Positives

• Director Kenny Myers received a significant equity grant of 100,000 shares, which aligns his interests more closely with those of shareholders.
• The grant demonstrates the company's commitment to compensating its board members with equity, utilizing the established Second Amended and Restated 2022 Equity Incentive Plan.
• An increase in insider ownership can signal confidence in the company's future prospects and long-term strategy.

Negatives

• The issuance of 100,000 shares, while a bonus, represents a slight dilution for existing shareholders, though this is a common aspect of equity compensation plans.

Future Outlook

NA

Industry Context

This transaction represents a standard equity compensation event for a director, a common practice across publicly traded companies to align the interests of board members with those of shareholders. It does not provide specific insights into broader industry trends.

Comparison to Industry Standards

• Equity grants to directors are a common practice in public companies, aligning their interests with shareholders. For example, many companies in the biotechnology or pharmaceutical sector (which 'MANGOCEUTICALS' might suggest) use equity compensation to attract and retain talent, similar to practices seen at companies like Pfizer or Moderna, where executive and director compensation packages often include significant stock options or restricted stock units.
• The specific amount of 100,000 shares would need to be benchmarked against MGRX's market capitalization and peer group compensation practices to assess its relative size, but the mechanism itself is standard.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders; potential minor dilution from the issuance of new shares.
• Board of Directors: Reinforces compensation structure and incentivizes continued service and commitment.

Key Dates

Recommendation

The acquisition of shares by a director, even as a bonus, is a positive indicator of insider confidence and alignment with shareholder interests. However, this single event, without additional financial or strategic information, is not sufficient to warrant a 'buy' recommendation. It supports a 'hold' position for existing investors, as it suggests stability and continued commitment from the board. For new investors, it's a neutral to slightly positive data point that should be considered alongside broader company performance and market conditions.

Keywords

MANGOCEUTICALS, MGRX, Kenny Myers, Director, Common Stock, Equity Incentive Plan, Insider Ownership, SEC Form 4, Stock Grant, Board of Directors